Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated B and is the 40th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
LH	LABCORP HOLDINGS INC	$30.12B	81,200,000	0.10%	1.62%	Net Selling	Net Selling
NEOG	NEOGEN CORP	$2.55B	218,306,034	0.11%	2.00%	Net Buying	Net Buying
CDNA	CAREDX INC	$4.24B	52,542,786	0.10%	29.38%	Net Selling	Net Selling
DGX	QUEST DIAGNOSTICS INC	$28.43B	110,019,073	0.10%	1.83%	Net Selling	Net Selling
SHC	SOTERA HEALTH CO	$4.65B	285,630,846	0.10%	4.47%	Net Selling	Net Selling
CSTL	CASTLE BIOSCIENCES INC	$1.06B	30,818,291	0.09%	14.94%	Net Selling	Net Selling
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$16.57B	47,917,467	0.12%	4.27%	Net Selling	Net Selling
DHR	DANAHER CORP	$166.11B	703,530,815	0.08%	26.03%	Net Selling	Net Selling
A	AGILENT TECHNOLOGIES INC	$50.15B	281,928,854	0.09%	1.29%	Net Buying	Net Buying
IQV	IQVIA HOLDINGS INC	$45.34B	164,800,000	0.10%	84.64%	Net Selling	Net Buying
NEO	NEOGENOMICS INC	$2.19B	129,389,465	0.11%	37.68%	Net Selling
WAT	WATERS CORP	$46.74B	98,285,634	0.10%	4.95%	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	$34.84B	19,890,405	0.10%	5.16%	Net Buying	Net Buying
TMO	THERMO FISHER SCIENTIFIC INC	$266.10B	370,515,868	0.09%	0.93%	Net Buying	Net Selling
QGEN	QIAGEN NV	$10.43B	206,497,000	0.07%	0.00%
BLLN	BILLIONTOONE INC	$5.35B	47,774,848	0.03%	18.61%	Net Selling	Net Selling
ILMN	ILLUMINA INC	$32.49B	151,200,000	0.10%	8.90%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$54.89B	78,786,265	0.09%	1.81%	Net Selling	Net Selling
MEDP	MEDPACE HOLDINGS INC	$18.59B	27,971,686	0.04%	99.96%	Net Selling	Net Selling
RVTY	REVVITY INC	$17.75B	111,586,401	0.10%	3.00%	Net Selling	Net Selling
STIM	NEURONETICS INC	$156.23M	77,728,311	0.05%	45.51%	Net Buying	Net Buying
BNR	BURNING ROCK BIOTECH LTD	$137.60M	108,604,241	0.00%	18.08%	Net Buying
FLGT	FULGENT GENETICS INC	$720.27M	27,939,000	0.06%	48.48%	Net Selling	Net Selling
RDNT	RADNET INC	$6.14B	78,774,892	0.10%	39.39%	Net Buying
ICLR	ICON PLC	$15.33B	74,916,724	0.11%	0.56%	Net Selling	Net Selling
PRPO	PRECIPIO INC	$42.34M	1,790,188	0.00%	100.00%	Net Buying	Net Buying
TWST	TWIST BIOSCIENCE CORP	$8.29B	62,707,424	0.12%	14.46%	Net Selling	Net Selling
QUCY	QUANTUM CYBER NV	$58.01M	84,068,192	0.00%	68.12%	Net Buying
NTRA	NATERA INC	$45.24B	145,004,521	0.09%	21.83%	Net Selling	Net Selling
GRAL	GRAIL INC	$5.61B	44,962,171	0.08%	18.29%	Net Selling	Net Selling
MYGN	MYRIAD GENETICS INC	$543.88M	95,922,196	0.09%	11.79%	Net Selling	Net Selling
BDSX	BIODESIX INC	$111.11M	11,088,511	0.01%	99.99%	Net Buying	Net Buying
OPK	OPKO HEALTH INC	$1.27B	742,506,477	0.03%	99.97%	Net Buying	Net Selling
GH	GUARDANT HEALTH INC	$21.02B	135,285,975	0.10%	43.52%	Net Selling	Net Selling
ACRS	ACLARIS THERAPEUTICS INC	$658.24M	158,612,149	0.08%	49.68%	Net Selling
XGN	EXAGEN INC	$127.43M	24,225,339	0.03%	57.51%	Net Buying	Net Selling
BIAF	BIOAFFINITY TECHNOLOGIES INC	$4.35M	1,820,006	0.02%	99.98%
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$80.83M	32,724,284	0.02%	99.98%	Net Buying
FRNM	FREENOME INC	$1.15B	107,021,669	0.01%	24.56%	Net Buying	Net Selling
TRIB	TRINITY BIOTECH PLC	$3.67M	12,473,555	0.01%	3.98%
XWEL	XWELL INC	$4.64M	8,589,266	0.00%	100.00%
VNRX	VOLITIONRX LTD	$2.51M	13,649,384	0.00%	100.00%	Net Selling	Net Selling
ISPC	ISPECIMEN INC	$1.86M	2,518,590	0.00%	100.00%
DRIO	DARIOHEALTH CORP	$23.42M	9,799,481	0.01%	99.99%	Net Buying
MBAI	MBODY AI LTD	$2.02M	1,002,929	0.00%	100.00%
PSNL	PERSONALIS INC	$1.72B	108,403,814	0.08%	33.78%	Net Buying	Net Selling
MDXH	MDXHEALTH SA	$713.97k	51,364,520	0.03%	83.20%	Net Buying	Net Buying
ADVB	ADVANCED BIOMED INC	$3.49M	1,652,133	0.00%	0.00%	Net Selling
NDRA	ENDRA LIFE SCIENCES INC	$7.15M	1,499,838	0.01%	89.48%
SERA	SERA PROGNOSTICS INC	$79.14M	39,769,839	0.04%	25.57%	Net Selling	Net Selling

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Nov 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) is the #1 top diagnostic & research stock out of 50 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Labcorp Holdings (NYSE:LH) is: Value: C, Growth: B, Momentum: B, Sentiment: C, Safety: A, Financials: C, and AI: C.

Labcorp Holdings (NYSE:LH) has a Due Diligence Score of 41, which is 12 points higher than the diagnostic & research industry average of 29.

LH passed 15 out of 38 due diligence checks and has strong fundamentals. Labcorp Holdings has seen its stock return 42.03% over the past year, overperforming other diagnostic & research stocks by 17 percentage points.

Labcorp Holdings has an average 1 year price target of $359.78, a downside of -2.99% from Labcorp Holdings's current stock price of $370.88.

Labcorp Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Labcorp Holdings, 55.56% have issued a Strong Buy rating, 11.11% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Neogen (NASDAQ:NEOG)

Neogen (NASDAQ:NEOG) is the #2 top diagnostic & research stock out of 50 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Neogen (NASDAQ:NEOG) is: Value: C, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: C, and AI: C.

Neogen (NASDAQ:NEOG) has a Due Diligence Score of 13, which is -16 points lower than the diagnostic & research industry average of 29. Although this number is below the industry average, our proven quant model rates NEOG as a "B".

NEOG passed 4 out of 33 due diligence checks and has weak fundamentals. Neogen has seen its stock return 83.49% over the past year, overperforming other diagnostic & research stocks by 58 percentage points.

Neogen has an average 1 year price target of $14.00, an upside of 19.97% from Neogen's current stock price of $11.67.

Neogen stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Neogen, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Caredx (NASDAQ:CDNA)

Caredx (NASDAQ:CDNA) is the #3 top diagnostic & research stock out of 50 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Caredx (NASDAQ:CDNA) is: Value: C, Growth: B, Momentum: A, Sentiment: A, Safety: C, Financials: C, and AI: D.

Caredx (NASDAQ:CDNA) has a Due Diligence Score of 53, which is 24 points higher than the diagnostic & research industry average of 29.

CDNA passed 18 out of 33 due diligence checks and has strong fundamentals. Caredx has seen its stock return 383.65% over the past year, overperforming other diagnostic & research stocks by 358 percentage points.

Caredx has an average 1 year price target of $72.67, a downside of -10.03% from Caredx's current stock price of $80.77.

Caredx stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Caredx, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 4.53%, which is 3 percentage points higher than the diagnostic & research industry average of 1.18%.

Qiagen Nv's dividend payout ratio of 255.5% indicates that its high dividend yield might not be sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.31%, which is the same as the diagnostic & research industry average of 1.18%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 33.2% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.78%, which is the same as the diagnostic & research industry average of 1.18%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 23.5% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.09% in the last day, and up 0.07% over the last week. Exagen was the among the top losers in the diagnostics & research industry, dropping -25.92% yesterday.

Exagen shares are trading lower after the company reported mixed Q3 financial results.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Sotera Health Co has a valuation score of 29, which is 16 points higher than the diagnostic & research industry average of 13. It passed 2 out of 7 valuation due diligence checks.

Sotera Health Co's stock has gained 3.37% in the past year. It has underperformed other stocks in the diagnostic & research industry by -22 percentage points.

2. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 43, which is 30 points higher than the diagnostic & research industry average of 13. It passed 3 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 17% in the past year. It has underperformed other stocks in the diagnostic & research industry by -8 percentage points.

3. Danaher (NYSE:DHR)

Danaher (NYSE:DHR) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Danaher has a valuation score of 29, which is 16 points higher than the diagnostic & research industry average of 13. It passed 2 out of 7 valuation due diligence checks.

Danaher's stock has gained 11.81% in the past year. It has underperformed other stocks in the diagnostic & research industry by -14 percentage points.

Are diagnostic & research stocks a good buy now?

57.14% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 2.57% over the next year.

0% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 28.21% of diagnostic & research stocks are rated B (Buy), 64.1% are rated C (Hold), 7.69% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 30.27x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.